Kelly L Bolton

List of Publications by Year
in descending order

51 papers	4,252 citations	186265 28 h-index	182427 51 g-index
56 all docs	56 docs citations	56 times ranked	7576 citing authors

#	Article	IF	Citations
1	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 132-141.	2.5	12
2	Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and metaâ€analysis. American Journal of Hematology, 2022, 97, 411-420.	4.1	11
3	Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes. Clinical Cancer Research, 2022, 28, 4947-4956.	7.0	22
4	The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation. Blood Reviews, 2021, 46, 100744.	5.7	16
5	Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors. Blood, 2021, 137, 2103-2113.	1.4	57
6	Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis. Nature Communications, 2021, 12, 338.	12.8	64
7	Clonal hematopoiesis is associated with risk of severe Covid-19. Nature Communications, 2021, 12, 5975.	12.8	81
8	Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms. Blood, 2021, 138, 3271-3271.	1.4	1
9	Effects of PARP Inhibitor Therapy on p53-Deficient Hematopoietic Stem and Progenitor Cell Fitness. Blood, 2021, 138, 3275-3275.	1.4	0
10	Clonal Hematopoiesis Is Associated with Risk of Cardiovascular Disease in Individuals with Human Immunodeficiency Virus. Blood, 2021, 138, 3277-3277.	1.4	0
11	What To Tell Your Patient With Clonal Hematopoiesis And Why: Insights From Two Specialized Clinics. Blood, 2020, 136, 1623-1631.	1.4	23
12	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	30.7	372
13	Chemotherapy and COVID-19 Outcomes in Patients With Cancer. Journal of Clinical Oncology, 2020, 38, 3538-3546.	1.6	195
14	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	21.4	367
15	Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature, 2020, 587, 477-482.	27.8	304
16	The Clinical Challenge of Clonal Hematopoiesis, a Newly Recognized Cardiovascular Risk Factor. JAMA Cardiology, 2020, 5, 958.	6.1	33
17	The Clinical Management of Clonal Hematopoiesis. Hematology/Oncology Clinics of North America, 2020, 34, 357-367.	2.2	42
18	Clonal Hematopoiesis and COVID-19 Severity in Cancer Patients. Blood, 2020, 136, 37-38.	1.4	1

#	Article	IF	Citations
19	Machine Learning for Prediction of Cancer-Associated Venous Thromboembolism. Blood, 2020, 136, 37-37.	1.4	1
20	Interplay between Chromosomal Alterations and Gene Mutations Shapes the Evolutionary Trajectory of Clonal Hematopoiesis. Blood, 2020, 136, 29-30.	1.4	0
21	Germline Contributions to Clonal Hematopoiesis in Solid Cancer Patients. Blood, 2020, 136, 30-31.	1.4	1
22	Clonal Hematopoiesis. Journal of the American College of Cardiology, 2019, 74, 567-577.	2.8	150
23	Managing Clonal Hematopoiesis in Patients With Solid Tumors. Journal of Clinical Oncology, 2019, 37, 7-11.	1.6	60
24	Single Cell DNA Sequencing Identifies Combinatorial Mutation Patterns and Clonal Architecture in Myeloid Malignancies. Blood, 2019, 134, 913-913.	1.4	1
25	TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes. Blood, 2019, 134, 675-675.	1.4	17
26	Extended Mutational Profiling By MSK-IMPACTTM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy. Blood, 2019, 134, 633-633.	1.4	1
27	Targeted Sequencing Predicts the Development of Myeloid Malignancies and Clinical Outcome in Patients with Unexplained Cytopenia. Blood, 2019, 134, 1712-1712.	1.4	1
28	Child protective services utilization of child abuse pediatricians: A mixed methods study. Child Abuse and Neglect, 2018, 76, 381-387.	2.6	5
29	Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. JAMA Oncology, 2018, 4, 1589.	7.1	139
30	Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays. Clinical Cancer Research, 2018, 24, 5918-5924.	7.0	84
31	Oncologic Therapy for Solid Tumors Alters the Risk of Clonal Hematopoiesis. Blood, 2018, 132, 747-747.	1.4	3
32	Characteristics of cases submitted to a statewide system of child abuse experts. Children and Youth Services Review, 2016, 67, 198-202.	1.9	6
33	Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. Clinical Cancer Research, 2015, 21, 652-657.	7.0	138
34	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
35	Gene Set Analysis of Survival Following Ovarian Cancer Implicates Macrolide Binding and Intracellular Signaling Genes. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 529-536.	2.5	7
36	Association Between <emph type="ital">BRCA1</emph> and <emph type="ital">BRCA2</emph> Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 382.	7.4	546

#	Article	IF	Citations
37	Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the ovarian cancer association consortium (OCAC). Journal of Internal Medicine, 2012, 271, 366-378.	6.0	46
38	A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival. BMC Cancer, 2011, 11, 119.	2.6	20
39	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research, 2011, 17, 3742-3750.	7.0	47
40	Collection of Forensic Evidence From Pediatric Victims of Sexual Assault. Pediatrics, 2011, 128, 233-238.	2.1	48
41	Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. Gynecologic Oncology, 2010, 119, 479-483.	1.4	26
42	Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics, 2010, 42, 880-884.	21.4	235
43	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics, 2010, 42, 874-879.	21.4	321
44	Assessment of Automated Image Analysis of Breast Cancer Tissue Microarrays for Epidemiologic Studies. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 992-999.	2.5	54
45	Association Between a Germline OCA2 Polymorphism at Chromosome 15q13.1 and Estrogen Receptorâ€"Negative Breast Cancer Survival. Journal of the National Cancer Institute, 2010, 102, 650-662.	6.3	48
46	Smoking, drinking and body weight after re-employment: does unemployment experience and compensation make a difference?. BMC Public Health, 2009, 9, 77.	2.9	40
47	HIV post-exposure prophylaxis in children and adolescents presenting for reported sexual assault. Child Abuse and Neglect, 2009, 33, 173-178.	2.6	21
48	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nature Genetics, 2009, 41, 996-1000.	21.4	276
49	ADHD latent class clusters: DSM-IV subtypes and comorbidity. Psychiatry Research, 2009, 170, 192-198.	3.3	42
50	Latent Class Subtyping of Attention-Deficit/Hyperactivity Disorder and Comorbid Conditions. Journal of the American Academy of Child and Adolescent Psychiatry, 2008, 47, 797-807.	0.5	73
51	Pinoresinol: A lignol of plant origin serving for defense in a caterpillar. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15497-15501.	7.1	73